Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 0 P" z5 h+ O: {) I) ~
- k8 p8 y, x3 L
$ X- ^* U6 f0 R2 K
Sub-category:5 h+ j( q1 M9 V# @6 ^6 E! k8 i5 ~
Molecular Targets
/ j' p' n* V8 a9 ~# t" H/ E4 i$ k
! d- b8 r; Q Q) r- b
, q1 C2 ^& ^9 c* pCategory:
4 {8 g% Y1 I {: W" {" t5 OTumor Biology , @) W' k4 w3 V! \) i
) ` z. V, ^1 C. |
; n$ R1 a" Q, R4 r1 M" [: ~Meeting:$ q8 k4 v; {* s% S
2011 ASCO Annual Meeting
2 T e) o t4 R' V* A6 G' c' l' p/ A" W6 c
; a+ `% t6 h* `* CSession Type and Session Title:1 k1 O k8 ^, ^; g5 d
Poster Discussion Session, Tumor Biology
4 h# ^! H5 w g' Z8 W& v
- r' P5 Y" M# O3 D% @1 E) ~$ m
) d2 G C0 W" T8 MAbstract No:
8 ]6 D: w4 {9 a8 x9 ?" {* F. p10517
8 [+ _; H& G" w3 G$ Q
$ d. W N; S w& A9 P* p
8 K, f% _" [; b6 FCitation:
/ p" w- F! d+ j- g2 OJ Clin Oncol 29: 2011 (suppl; abstr 10517)
' [/ e, L6 s& {6 x" i0 J# H2 w
- ?$ T# ]& R* U$ R7 F) d! o/ ~
. H/ ^- R# K1 K1 _Author(s):
* T7 N# U! |6 G: j bJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 5 I0 Y3 u" ]5 R. e/ W5 r
1 U* K9 A' P' x7 K
* A& O& } v7 S( g4 T: d* e. J+ ^0 e
' @4 z# t+ d, ]# B+ IAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
$ X+ ?& w9 g+ a, ^( s0 H# l' N, F) Q
Abstract Disclosures
& p! @" U: |& p$ n4 i6 P% E8 V Q1 i4 g ^- J3 P8 q3 y+ ?
Abstract:
, a; G: T7 W! w' D5 ?) x+ k
* a/ D" Z( a7 g
6 B: w5 d4 C' f/ M4 I) Z& iBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ E# n2 V3 q/ c R q3 I# a( X% e' `+ q5 ]) `% x0 Z3 v. x
3 X6 q& f1 d# r/ i) V
|
有了解脾转移的病友吗
肺腺癌1A3期，术后一个月复查，CT平扫脾脏内多发低密度影，增强核磁报脾脏多发转移，
肺鳞癌晚期病灶大幅缩小，骨转却不断
62岁的父亲几个月前查出肺鳞癌晚期全身多处转移，目前K药单免中，大部分病灶和转移灶
父亲晚期肺癌即将迈入第7年，这是我
讲述者：郭先生整理者：pear
2018年4月底，父亲因长期右肩胛骨疼痛、脸部及颈部肿大而
肺腺癌3a期术后应该化疗加靶向还是单
术前CT显示无任何淋巴结肿大，但原发灶有胸膜牵拉，血管集束，且有多发小结节（外科认
首个击败奥希替尼的药物组合获批！显
作者：seacat
2024年8月20日，强生宣布美国FDA批准埃万妥单抗(Amivantamab)+兰泽替尼
显身卡
